COPENHAGEN, Sept 14 (Reuters) - U.S. drugmaker Eli Lilly and Co. (LLY.N: Quote, Profile, Research) said it was ready for a head-to-head competition on the diabetes treatment market with Denmark’s Novo Nordisk (NOVOb.CO: Quote, Profile, Research), the world’s biggest maker of insulin.>>> Discuss This Story
